Lab-Grown Esophagus Offers Hope for Children with Rare Condition

A groundbreaking advancement in regenerative medicine offers a potential lifeline for children born with long-gap esophageal atresia (LGOA), a rare and life-threatening condition. Scientists have successfully engineered a functional esophagus in the lab, demonstrating its ability to restore normal swallowing and growth in preclinical trials. This innovation could eliminate the need for complex surgeries and long-term immunosuppression, offering a significantly improved quality of life for affected children.

Understanding Long-Gap Esophageal Atresia

LGOA is a birth defect where the esophagus, the tube connecting the mouth to the stomach, is separated by a significant gap. Approximately 180 babies are born with esophageal atresia (OA) in the UK each year, with around 10% having LGOA ¹. Babies with LGOA cannot survive without surgical intervention, but the large gap often prevents immediate repair. Current treatments involve prolonged feeding via a tube and complex surgeries, including gastric pull-ups, which can lead to further complications like acid reflux and lung disease ¹.

The Breakthrough: Engineering a Fresh Esophagus

Researchers at Great Ormond Street Hospital (GOSH) and University College London (UCL) have pioneered a technique to create a fully circumferential, lab-grown esophagus ². The process involves creating a scaffold using a donor pig’s esophagus, which is then stripped of all pig cells – a process called decellularization ³. Muscle cells are then harvested from the recipient animal (in this case, pigs) and grown in the lab before being injected into the scaffold ¹.

The seeded scaffold is then nurtured in a specialized container with growth fluids for one week, allowing the cells to populate and develop into functional tissue ¹. The resulting lab-grown esophagus develops nerves, blood vessels, and muscle, enabling it to contract and move like a natural esophagus ¹.

Promising Results in Preclinical Trials

In trials conducted on pigs, the lab-grown esophagus successfully restored normal swallowing and growth without the need for immunosuppressant drugs ¹. All eight pigs survived the first 30 days after the transplant, and five remained alive after six months ¹. Importantly, as the graft utilizes the recipient’s own cells, it is recognized as self-tissue, minimizing the risk of rejection ².

Timeline and Future Outlook

Researchers are optimistic that this engineered tissue treatment could be available for human patients within five years ¹. The team envisions storing different sized scaffolds ready for personalization for newborns or children with LGOA, with biopsies taken during routine feeding tube placement ¹. This breakthrough builds upon decades of research and represents a significant step forward in regenerative medicine, potentially offering a life-changing solution for children with this devastating condition.

One family, whose two-year-old son has spent half his life in hospital with LGOA, described the potential treatment as “life-changing” ¹.